Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1 EAST HANOVER, N.J., July 3, 2025 /PRNewswire/ -- Novartis...